Monday's NASDAQ Winners: SIGA, ARNA, VRNM, GRVY
Linkedin

Monday's NASDAQ Winners: SIGA, ARNA, VRNM, GRVY

New York City : NY : USA | Mar 27, 2012 at 8:09 AM PDT
XX XX
Views: Pending
 

New York, NY - March 27, 2012 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for Monday March 26th. The Nasdaq Composite surged 54.65 (1.78%) to end at 3,122.57.

SIGA Technologies, Inc. (NASDAQ: SIGA) shares soared 29.26% to close at $3.49 without any official news. The stock has been showing strong support at $2 and has jumped over 38% so far this year. Yesterday's volume was impressive with more than 2.95 million shares traded, compared to its average volume of 355K shares.

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced that the European Medicines Agency (EMA) has accepted the filing of a Marketing Authorization Application (MAA) for lorcaserin, used for weight control, in patients who are obese or overweight and have at least one weight-related co-morbid condition. Shares of the company gained 24.90% to $3.01 in the last trading session.

Also, the U.S. Food and Drug Administration advisory committee will meet May 10 to discuss the company's resubmitted application for lorcaserin.

Verenium Corporation (NASDAQ: VRNM) moved 19.81% to close at $3.69 after it closed a transaction with DSM Food Specialties B.V., in which Verenium has sold to DSM its Oilseed Processing business, licensed certain enzymes for use in the food and beverage markets, and will provide access to new gene libraries to be developed by Verenium. Verenium will receive $37 million in total consideration, including transaction and related expenses, on March 26, 2012.

Gravity Co., LTD. (NASDAQ: GRVY) rose 15.99% and closed at $3.41after the company announced that Ragnarok Online II was commercially launched in Korea on March 26, 2012. After launching Ragnarok Online II in Korea, the company intends to release the game in a couple of overseas markets in 2012 as well.

Get Free investor news and stock alerts

Sign Up: http://www.investorideas.com/Resources/Newsletter.asp

Join Investor Ideas Get 13 of the best stock directories online;

Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks

Join: http://www.investorideas.com/membership/

About InvestorIdeas.com:

InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp

800-665-0411 - Source - www.Investorideas.com

Investorideas is based in Bellingham, Washington, United States of America, and is a Stringer on Allvoices.
Report Credibility
 
  • Clear
  • Share:
  • Share
  • Clear
  • Clear
  • Clear
  • Clear
 
 
 
Advertisement
 

News Stories

 
  • NYSE & NASDAQ Smallcaps Trend Higher On Bullish News

    Sign up for weekly Technical and Equity Research Reports covering all equity sectors. March 26, 2012 Primero Mining Corp. has moved up for recovery today as investors accumulate shares from last week’s selling. The stock is up $.19 (7.95%) bringing...
  • Will Obesity Drugs Do Better in Europe?

      The Motley Fool
    While I have no idea how that might justify the 35% move we saw in the stock in the two days following, it does seem like lorcaserin might have a slightly better chance at approval there. Contrave were all rejected by the Food and Drug Administration...

Blogs

 >

More From Allvoices

Report Your News Got a similar story?
Add it to the network!

Or add related content to this report



Use of this site is governed by our Terms of Use Agreement and Privacy Policy.

© Allvoices, Inc. 2008-2014. All rights reserved. Powered by PulsePoint.